Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics Public Limited Company - Ordinary Shares (NQ:HZNP)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Horizon Therapeutics Public Limited Company - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Daxdilimab for the Treatment of Systemic Lupus Erythematosus (SLE) Did Not Meet Primary Endpoint
From Horizon Therapeutics plc
Via Business Wire
The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023
Trading below a 15 forward price-to-earnings, these undervalued pharma stocks offer opportunities in an overbought market. 
Via InvestorPlace
Tesla On Tap: "Mega-cap" Reporting Season Gets Underway After Close With EV Giant's Earnings
(Wednesday market open) Major indexes ride into Tesla’s (NASDAQ: TSLA) earnings later today on a long winning streak that carried stocks to new 15-month highs yesterday. Hopes for an economic “soft... 
Via Benzinga
Is Amgen a Good Dividend Stock?
The biotech's yield is near an all-time high right now. 
Via The Motley Fool
Horizon Therapeutics plc to Release Second-Quarter 2023 Financial Results on Aug. 8, 2023
From Horizon Therapeutics plc
Via Business Wire
Activision Surges 10% As Judge OK's Microsoft Acquisition Deal
Following a federal judge's OK of Microsoft's acquisition, Activision shares soared 10%, marking their strongest performance in over a year. The FTC can appeal. 
Via MarketBeat
Activision Stock Jumps As U.S. Judge Clears Hurdle To Microsoft Buyout
Activision stock rocketed after a court allowed Microsoft to proceed with its $69 billion acquisition of the video game publisher. 
Via Investor's Business Daily
Why Shares of Viridian Therapeutics Are Falling Tuesday
The company announced preliminary trial results for its lead therapy. 
Via The Motley Fool
Viridian Wants To Take On Horizon; Why This Update In Thyroid Eye Disease Fell Flat
Shares tumbled after the biotech company unveiled the results of its chronic TED treatment. 
Via Investor's Business Daily
Treasury Yields Spiking As Market Looks Ahead To Jobs Data, Raising Valuation Concerns
(Thursday market open) Things are heating up, and we’re not just talking about the July weather. A week from the start of Q2 earnings season, Wall Street is on tenterhooks awaiting tomorrow’s crucial... 
Via Benzinga
Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology
From Horizon Therapeutics plc
Via Business Wire
3 Biotech Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2025
In researching this article, we used AI to help make predictions for potential triple-digit return biotech stocks by 2025 
Via InvestorPlace
New Analysis of MRI Findings Shows UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
What Will Amgen Buy Next?
The biotech could pursue these two budget-friendly targets. 
Via The Motley Fool
Activision Blizzard Shares up 1.83% Amid Regulators' Blunders
Shares of Microsoft Corp. (NASDAQ: MSFT) declined 1.92% on June 26, more than the broader market, while Activision Blizzard Inc. (NASDAQ: ATVI) rose 1.83%. The S&P 500 declined 0.41% in the session. 
Via MarketBeat
Topics Stocks
Why Amgen Stock Slumped on Monday
Already under fire on the regulatory front, the company is hit with a price-target cut. 
Via The Motley Fool
TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration
From Horizon Therapeutics plc
Via Business Wire
New Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials and Real-World Analyses Shed Light on Link Between Thyroid Autoimmunity and Hearing Risks
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement
From Horizon Therapeutics plc
Via Business Wire
UPLIZNA® (inebilizumab-cdon) Pivotal Trial Publication Integrating MRI and Biomarker Evaluation Shows Accuracy and Uniformity of Attack Diagnoses for Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Is AbbVie or Amgen the Better Bargain Buy Right Now?
These elite drugmakers are both working through a number of headwinds. 
Via The Motley Fool
Horizon Therapeutics plc announces premium partnership with KPMG Women’s Irish Open
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting
From Horizon Therapeutics plc
Via Business Wire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
3 Undervalued Biotech Stocks to Buy Before They Blast Off
Fundamental analysis makes these three undervalued biotech stocks to buy plus they have other catalysts that make them compelling. 
Via InvestorPlace
Biomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA® (inebilizumab-cdon)
From Horizon Therapeutics plc
Via Business Wire
Presentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’s Syndrome
From Horizon Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.